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ABSTRACT
Introduction: The Apixaban for the Reduction
in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE), Randomized
Evaluation of Long-term Anticoagulation
Therapy (RE-LY), and Rivaroxaban Once Daily
Oral Direct Factor Xa Inhibition Compared with
Vitamin K Antagonism for Prevention of Stroke
and Embolism Trial in Atrial Fibrillation
(ROCKET-AF) trials demonstrated that the oral
anticoagulants (OACs), apixaban, dabigatran,
and rivaroxaban, respectively, are efficacious for
stroke prevention among nonvalvular atrial
fibrillation (NVAF) patients. Based on clinical
trial results this study evaluated medical costs of
clinical events associated with use of individual
OACs relative to those of warfarin in NVAF
patients with moderate and high stroke risk.
Methods: Rates for primary and secondary
efficacy and safety outcomes (i.e., clinical
events) among NVAF patients with
CHADS2 = 2 and C3 were determined from the
three OAC trials. One-year incremental costs
among patients with clinical events from a US
payer perspective were obtained from the
literature and inflation adjusted to 2010 costs.
Medical costs for clinical events associated with
each OAC vs. warfarin were estimated and
compared.
Results: For NVAF patients with moderate
stroke risk (CHADS2 = 2) differences in clinical
event medical costs vs. warfarin were -$298,
-$143, and ?$117 per patient year for apixaban,
dabigatran (150 mg), and rivaroxaban,
respectively (negative numbers indicate cost
reduction). For NVAF patients with high stroke
risk (CHADS2 C 3) differences in clinical event
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medical costs vs. warfarin were -$697, ?$2, and
-$100 for apixaban, dabigatran (150 mg), and
rivaroxaban, respectively.
Conclusions: Medical cost differences
associated with OACs vs. warfarin vary
according to stroke risk. Of the three OACs,
apixaban demonstrated consistent medical cost
reductions vs. warfarin for NVAF patients with
moderate and high stroke risks.
Keywords: Apixaban; Atrial fibrillation;
Dabigatran; Stroke prevention; Oral
anticoagulants; Rivaroxaban
INTRODUCTION
Nonvalvular atrial fibrillation (NVAF) is a
cardiac rhythm disorder, which increases
stroke risk approximately fivefold and affects
[5 million Americans [1, 2]. Warfarin is
efficacious for reducing stroke risk among
NVAF patients, but its use has limitations,
including a narrow therapeutic range,
significant drug–drug interactions, and an
increased risk for major bleeding events, all of
which can be exacerbated for those with
comorbidities and/or who are C75 years of
age [3, 4]. The Apixaban for the Reduction in
Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE), Randomized
Evaluation of Long-term Anticoagulation
Therapy (RE-LY), and Rivaroxaban Once Daily
Oral Direct Factor Xa Inhibition Compared with
Vitamin K Antagonism for Prevention of Stroke
and Embolism Trial in Atrial Fibrillation
(ROCKET-AF) trials demonstrated that the oral
anticoagulants (OACs), apixaban, dabigatran
(150 mg), and rivaroxaban, respectively, are at
least as efficacious as warfarin for stroke
prevention among NVAF patients [5–7]. NVAF
patients included in these trials differed in
stroke risk from those in the ROCKET-AF trial
in having a mean CHADS2 score of 3.5, while
those included in the other trials had mean
CHADS2 scores of 2.1 [5–7]. Medical costs for
clinical events among the overall NVAF
population using any of the OACs vs. warfarin
were estimated to be lower [8]. However, these
results may differ for patients with different
stroke risks. This study compared medical costs
for clinical events of NVAF patients in the OAC
vs. warfarin trials with moderate (CHADS2 = 2)
and higher stroke risk (CHADS2 C 3) treated
with individual OACs vs. warfarin from a US
payer perspective.
MATERIALS AND METHODS
Clinical event rates (stroke/systemic embolism
(SSE), myocardial infarction (MI), pulmonary
embolism/deep vein thrombosis (PE/DVT),
major bleeding events excluding hemorrhagic
stroke (MBEHS), non-major bleeding events)
among NVAF patients with CHADS2 = 2 and C3
treated with individual OACs or warfarin were
determined from the three OAC trials [5–7]
(Table 1). Hemorrhagic stroke (HS) was
considered as an efficacy and safety end point in
the OAC vs. warfarin trials. To avoid costing twice,
HS events were excluded from major bleeding
events, but kept grouped with SSE. MBEHS rate
was defined as the absolute event rate of major
bleeding events minus HS. When the event rate
for a particular clinical event was not reported in a
clinical trial, the rate of an end point containing
this clinical event was used [8]. The event rates of
non-major bleeding events, including clinically
relevant non-major bleeding events and other
minor bleeding events, were not reported by
stroke risk groups in the original clinical trial
publications. In this analysis we assumed the
relative risks of these non-major bleeding events
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for NVAF patients with different stroke risks to
be the same as those for major bleeding
events reported for each trial. These estimated
relative risks of non-major bleeding events in
combination with the absolute event rates of
non-major bleeding events from the overall trial
population were used to estimate the event rates
of non-major bleeding events for the stroke risk
groups. The event rates of the secondary end
points, MI, and PE/DVT were assumed to be the
same as those of the overall trial population since
such stroke risk group-specific data were not
reported in the OAC vs. warfarin clinical trials.
One-year incremental costs (US payer
perspective) for clinical events were obtained
and adjusted to 2010 costs [8, 9]. Based on the
absolute risks for each of the clinical events,
differences in medical costs associated with
each OAC vs. warfarin were determined. Drug
costs and monitoring expenses were not
evaluated.
We additionally carried out a sensitivity
analysis in which rates of clinical events for
warfarin-treated NVAF patients were estimated
as weighted averages from the three OAC trials
by patient count. The absolute risks of events
associated with OACs were derived by applying
trial relative risks to the weighted average of
warfarin event rates producing event rate
estimates for each OAC for NVAF patients
with CHADS2 = 2 and CHADS2 C3.
The authors conformed to the Helsinki
Declaration of 1975, as revised in 2000
concerning human and animal rights, and
Springer’s policy concerning informed consent
has been followed.
RESULTS
One-year medical costs of clinical events were as
follows: SSE = $40,613 [10, 11], MI = $37,446
[12], PE/DVT = $19,532 [13], MBEHS = $34,617
Table 1 Estimated absolute risks for clinical events among NVAF patients at moderate and high stroke risk













CHADS2 52 ‡3 52 ‡3 52 ‡3 52 ‡3 52 ‡3 52 ‡3
SSE 1.40 2.80 1.20 1.90 1.38 2.68 0.84 1.88 2.15 2.44 1.79 2.15
MIa 0.61 0.61 0.53 0.53 0.53 0.53 0.74 0.74 1.12 1.12 0.91 0.91
PE/DVTa 0.05 0.05 0.04 0.04 0.09 0.09 0.15 0.15 NR NR NR NR
MBEHS 2.59 3.39 2.08 2.55 3.00 4.01 2.97 4.69 3.29 2.85 4.26 3.13
Non-major
bleeding eventsb
22.71 22.71 17.41 15.68 16.37 16.37 15.03 17.26 13.43 13.43 16.31 13.87
ARISTOTLE apixaban for the reduction in stroke and other thromboembolic events in atrial ﬁbrillation, MBEHS major bleeding events
excluding hemorrhagic stroke, MI myocardial infarction, NR not reported, NVAF nonvalvular atrial ﬁbrillation, PE/DVT pulmonary
embolism/deep vein thrombosis, RE-LY randomized evaluation of long-term anticoagulation therapy, ROCKET-AF rivaroxaban once
daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial ﬁbrillation
a Rates of MI and PE/DVT were not reported by CHADS2 score and those from the overall trial population were used [8]
b Relative risks of non-major bleeding events were assumed to be the same as major bleeding events in each trial, and these in combination
with absolute event rates of non-major bleeding events from the overall trial populations were used for estimations of event rates
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[10], non-major bleeding event = $130 [8, 14]. In
a year, overall medical cost differences associated
with apixaban, dabigatran, and rivaroxaban use
relative to warfarin among NVAF patients with
CHADS2 = 2 were estimated at -$298, -$143,
and $117, respectively (negative numbers
indicate cost reduction), and among those with
CHADS2 C 3 were estimated at -$697, $2, and
-$100, respectively (Table 2).
In the sensitivity analysis, in which rates of
clinical events for warfarin were estimated as
weighted averages from the three OAC trials
Table 2 Estimated differences in medical costs for clinical events among NVAF patients at moderate and high stroke risk
Trial ARISTOTLE RE-LY ROCKET-AF
Drug Apixaban ($/patient-year) Dabigatran ($/patient-year) Rivaroxaban ($/patient-year)
CHADS2 52 ‡3 52 ‡3 52 ‡3
SSE -$81 -$366 -$219 -$325 -$143 -$119
MI -$30 -$30 $79 $79 -$79 -$79
PE/DVT -$2 -$2 $12 $12 NR NR
MBEHS -$178 -$290 -$13 $236 $334 $97
Non-major bleeding events -$7 -$9 -$2 $1 $4 $1
Total -$298 -$697 -$143 $2 $117 -$100
ARISTOTLE apixaban for the reduction in stroke and other thromboembolic events in atrial ﬁbrillation, MBEHS major
bleeding events excluding hemorrhagic stroke, MI myocardial infarction, NR not reported, NVAF nonvalvular atrial
ﬁbrillation, PE/DVT pulmonary embolism/deep vein thrombosis, RE-LY randomized evaluation of long-term
anticoagulation therapy, ROCKET-AF rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K
antagonism for prevention of stroke and embolism trial in atrial ﬁbrillation
Table 3 Sensitivity analysis: estimated differences in medical costs for clinical events among NVAF patients at moderate
and high stroke risk
Trial ARISTOTLE RE-LY ROCKET-AF
Drug Apixaban ($/patient-year) Dabigatran ($/patient-year) Rivaroxaban ($/patient-year)
CHADS2 52 ‡3 52 ‡3 52 ‡3
SSE -$87 -$366 -$239 -$312 -$100 -$126
MI -$35 -$35 $79 $79 -$56 -$56
PE/DVT -$3 -$3 $8 $8 -$2 -$2
MBEHS -$201 -$282 $3 $224 $287 $119
Non-major bleeding events -$5 -$7 -$2 $1 $5 $1
Total -$332 -$664 -$151 $0 $135 -$63
ARISTOTLE apixaban for the reduction in stroke and other thromboembolic events in atrial ﬁbrillation, MBEHS major
bleeding events excluding hemorrhagic stroke, MI myocardial infarction, NR not reported, NVAF nonvalvular atrial
ﬁbrillation, PE/DVT pulmonary embolism/deep vein thrombosis, RE-LY randomized evaluation of long-term
anticoagulation therapy, ROCKET-AF rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K
antagonism for prevention of stroke and embolism trial in atrial ﬁbrillation
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and those of individual OACs as relative risks to
the common warfarin event rates, overall
medical cost differences associated with
apixaban, dabigatran, and rivaroxaban use
relative to warfarin among NVAF patients with
CHADS2 = 2 were estimated at -$332, -$151,
and $135, respectively, and among those with
CHADS2 C 3 were estimated at -$664, $0, and
-$63, respectively (Table 3).
DISCUSSION
Differences in medical costs for OACs
compared with warfarin are dependent on the
specific OAC used and stroke risk. In this
analysis, only apixaban use was associated
with consistently reduced medical costs
relative to warfarin for NVAF patients with
moderate or high stroke risk. The primary
drivers for medical cost reductions associated
with apixaban use, relative to warfarin, were
reduced rates of SSE, which were 14% and 32%
lower, and MBEHS, which were 20% and 25%
lower, for NVAF patients with CHADS2 = 2 and
CHADS2 C 3, respectively. The use of either
dabigatran or rivaroxaban instead of warfarin
was associated with lower risks for SSE, but not
consistently lower risks for other clinical
events and, therefore, their cost differences
were less.
This analysis was based on clinical trial data
and the application of the results to routine
clinical practice requires further assessment.
Since the occurrences of stroke and major
bleeding events may be greater in routine
clinical practice [15], the cost differences may
have been underestimated. Additionally, when
major bleeding events and HS relative rates were
originally reported as hazard ratios, the analysis
measured the relative risk of ‘‘time to first event’’
[5–7]. The subtraction approach used in this
analysis did not consider any impact of timing
and, thus, may have underestimated the rate of
MBEHS.
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